Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers

Saqib Islam, Beeline Medicines CEO (Photo courtesy of Copper Hound Pictures) June 30, 2026 07:00 AM EDTUpdated 09:54 AM FinancingStartups Bee­line adds $126M to Bain-backed im­munol­o­gy pipeline from Bris­tol My­ers Kyle LaHucik Biotech Correspondent Bris­tol My­ers Squibb spin­out Bee­line Med­i­cines is get­ting ex­tra love from its ex­ist­ing back­ers and some of its man­age­ment team. Bain Cap­i­tal, the Cana­da Pen­sion … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER